TLR9 and neoplasm: Similar studies have shown that the ability of toll-like receptor 9 (TLR9) agonists, such as CpG oligonucleotides, to increase the anti-tumor activity of cisplatin is associated with drug-induced downregulation of some DNA repair genes in tumors, thus making tumor cells more vulnerable to DNA damage [57,58].